LINC-3
2020
Osilodrostat in Cushing's Disease (LINC-3)
In 137 adults with Cushing's disease, osilodrostat achieved control of mean 24-h urinary free cortisol in a randomised-withdrawal phase versus placebo.
Result
Efficacy: Maintained mUFC control during 8-week withdrawalOR 13.7 · P < 0.0001
Below 1 favours placebo, above 1 favours osilodrostat.
- Absolute difference
- 57 points
- NNT
- 2
Absolute difference and NNT are derived from the event rates.
- Subtopic
- Cushing's disease
- Design
- Phase 3 with randomised withdrawal at week 26
- Relevance
- Supporting: context rather than must-know.
- Source
- Pivonello R, et al. Lancet Diabetes Endocrinol. 2020;8(9):748-761.doi 10.1016/S2213-8587(20)30240-0
Discussion & critique
Basis of the Isturisa approval for Cushing's disease: oral steroidogenesis inhibitor with predictable cortisol-lowering.